Fertility concerns influence treatment decisions in younger patients with breast cancer
the ONA take:
Previous studies have shown that following a 5-year course of tamoxifen after breast cancer treatment can reduce recurrence by 47% and mortality by 26%.
In addition, more recent data suggests taking tamoxifen for 10 years may be even more beneficial. However, many patients with breast cancer, especially premenopausal women, decline the therapy or discontinue it in less than 5 years.
This study found that 13% of patients declined tamoxifen therapy and 16% stopped before the recommended 5 years of treatment were up.
Phone interviews conducted with 88 patients who did not initiate or discontinued tamoxifen revealed concerns about fertility and side effects were primary factors for these patients’ decision.
The researchers conclude these findings demonstrate a need to include appropriate counseling for patients who express concerns about future fertility at the outset as part of a multidisciplinary treatment plan.
They suggested that a dialog about fertility could identify more patients willing to complete the recommended course if they could delay or take a break from the therapy to allow for pregnancy.
A new international trial, called POSITIVE, being conducted by the International Breast Cancer Study Group, is looking at whether premenopausal women who take a hiatus to become pregnant then resume the therapy would have similar benefit as those who taken tamoxifen continuously for 5 years.
Previous studies have shown that following a 5-year course of tamoxifen after breast cancer treatment can reduce recurrence.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|